Advertisement
Canada markets close in 6 hours 27 minutes
  • S&P/TSX

    22,163.77
    +56.69 (+0.26%)
     
  • S&P 500

    5,246.95
    -1.54 (-0.03%)
     
  • DOW

    39,836.42
    +76.34 (+0.19%)
     
  • CAD/USD

    0.7371
    -0.0002 (-0.02%)
     
  • CRUDE OIL

    82.43
    +1.08 (+1.33%)
     
  • Bitcoin CAD

    96,239.96
    -986.29 (-1.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,232.50
    +19.80 (+0.89%)
     
  • RUSSELL 2000

    2,114.35
    +44.19 (+2.13%)
     
  • 10-Yr Bond

    4.2160
    +0.0200 (+0.48%)
     
  • NASDAQ

    16,356.93
    -42.59 (-0.26%)
     
  • VOLATILITY

    12.95
    +0.17 (+1.33%)
     
  • FTSE

    7,956.76
    +24.78 (+0.31%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6817
    +0.0012 (+0.18%)
     

Today’s Research Reports on Stocks to Watch: MYnd Analytics and Exact Sciences

NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Exact Sciences made headlines on Wednesday, announcing an agreement with Pfizer to share marketing expenses and to co-promote the company’s Colorguard colorectal cancer screening test. Shares of MYnd Analytics also saw big gains with the company announcing that it was invited to present at the 2018 Military Health System Research Symposium.

RDI Initiates Coverage on:

MYnd Analytics, Inc.
https://rdinvesting.com/news/?ticker=MYND

Exact Sciences Corporation
https://rdinvesting.com/news/?ticker=EXAS

MYnd Analytics, Inc. shares closed up 21.54% on Wednesday with about 2.6 million shares traded. Average trading volume for the stock is just 355,137 shares. There was no major news from the company aside from the announcement that its CEO, George Carpenter, presented at the 2018 Military Health System Research Symposium (MHSRS), held in Kissimmee, Florida from August 20th through 23rd. The press release stated, "The presentation, co-authored by Mr. Carpenter and Dr. Mark Schiller, MYnd’s Medical Director, covered topics including the growing clinical evidence supporting the use of the Company’s Psychiatric EEG Evaluation Registry (PEER) report to improve patient outcomes, including reduced suicidal ideation, by providing physicians with objective, personalized data to assist in the selection of appropriate medications." Last week the company announced an agreement to provide neuropsychiatric testing for the Inova Health System (Inova), a global leader in personalized health serving more than 2 million people each year across the Washington, DC, metro area and beyond.

ADVERTISEMENT

Access RDI’s MYnd Analytics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MYND

Exact Sciences Corporation shares were on fire yesterday, closing the day up 30.51% on trading volume roughly five times higher than usual. It was an agreement with giant Pfizer that sent shares flying. Exact Sciences Corp. announced that Pfizer would share marketing expenses and co-promote the company's stool screening test for colorectal cancer, Colorguard. Exact Sciences Chief Executive Officer Kevin Conroy told Reuters in an interview, "The marketing effort will begin in the fourth quarter (and) we expect the impact (of it) to occur next year." He also had said, "This partnership marks a turning point in the fight to end colorectal cancer. Pfizer is joining Exact Sciences' mission of eradicating colorectal cancer by helping detect the disease at its earliest, most treatable stages. Together we can help reduce the prevalence of colorectal cancer by combining the power of Cologuard and the talented Exact Sciences team with Pfizer's experience, relationships and resources." Currently the company is investing about $80 million in advertising and promoting Cologuard. "This story has always been about driving uptake more so than profitability over the next few years, and this should accomplish this nicely," remarked Brian Weinstein analyst William Blair. The company also reaffirmed its revenue forecast for this year and said it expects roughly $700 million in 2019. Analysts on average are expecting $611 million for 2019.

Access RDI’s Exact Sciences Corporation Research Report at:
https://rdinvesting.com/news/?ticker=EXAS

Our Actionable Research on MYnd Analytics, Inc. (NASDAQ: MYND) and Exact Sciences Corporation (NASDAQ: EXAS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com